A specialized 3-D printing extruder developed by a University of Alabama in Huntsville (UAH) sophomore and his collaborator could lower the costs of printing cellular structures for use in drug testing.
Detailed prediction models that project long-term patient mortality following PCI and CABG surgery can be useful for the heart team when determining the best treatment strategy for individual patients
Dana-Farber Cancer Institute scientists have developed a mathematical model to predict how a patient’s tumor is likely to behave and which of several possible treatments is most likely to be effective.
Clinical laboratory experts and physicians at Dartmouth-Hitchcock Norris Cotton Cancer Center achieved 100 percent accuracy using new gene sequencing equipment and panels to test for abnormal DNA in cancerous tumor cells, paving the way for routine genetic testing in personalizing cancer care
A research team from Roswell Park Cancer Institute and the Ocean University of China has published its latest preclinical findings about the promising antitumor agent FL118, reporting new insights about the agent's chemical structure.
Physicians in the Neonatal Intensive Care Unit in the Maxine Dunitz Children’s Health Center launched a pilot study in which mothers’ breast milk is analyzed to determine whether premature infants are receiving the correct amounts of nutrients they need to thrive. The study could lead to a new innovation in personalized medicine: Individually optimized nutrition for the smallest patients.
A web research tool is helping cancer researchers and physicians make sense out of genetic data from nearly 100,000 patients and more than 50,000 mice. The Gene Expression Barcode 3.0 is a vital resource in the new era of personalized medicine.
The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.
An international, multidisciplinary research team has developed an ultrathin membrane that can stick to skin and carry arrays of diagnostic sensors and stimulatory components. The “electronic skin” allows remote patient monitoring and may someday be used to deliver treatments.
Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. The answer may lie in your genes, but professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate).
Technion scientists have moved a step closer to creating custom medical treatment plans based on a patient's DNA, pinpointing the root of a patient's illness and making sure treatment will not cause a fatal allergic reaction.
For the past two years, Wu Feng has led a research team that has now created a new generation of efficient data management and analysis software for large-scale, data-intensive scientific applications in the cloud. “Our goal was to keep up with the data deluge in the DNA sequencing space. Our result is that we are now analyzing data faster, and we are also analyzing it more intelligently,” Feng said.
A new technique successfully takes on a longstanding challenge in DNA sequencing – determining whether a particular genetic sequence comes from an individual's mother or father. The method, described in a Ludwig Cancer Research study in Nature Biotechnology, promises to accelerate studies of how genes contribute to disease, improve the process of matching donors with organs and help scientists better understand human migration patterns.
Johns Hopkins scientists have developed new drugs that — at least in a laboratory dish — appear to halt the brain-destroying impact of a genetic mutation at work in some forms of two incurable diseases, amyotrophic lateral sclerosis (ALS) and dementia.
As a woman in her mid-forties who didn’t smoke, Elizabeth Lacasia never expected to be diagnosed with lung cancer. But in 2006, after she developed a persistent and serious cough, a chest X-ray and CT scan revealed several tumors in her lower left lung.
Vanderbilt has added genetic screening for the drug tacrolimus to its personalize medicine pharmacogenomics program PREDICT. The new drug screening protocol was added following data that shows a single genetic variation largely impacts different dose requirements for patients.
Dr. Vittorio Cristini, at the UNM Cancer Center, and his colleagues have just published a paper describing their mathematical model of cancer. The model uses physics and the patient's own tumor information to accurately predict treatment outcomes.
Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual’s genetics.
A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.
Geisinger Health System announced plans to partner with Indivumed, a leading provider of services enabling individualized cancer therapy.
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, have enhanced a device they developed to identify and “grab” circulating tumor cells, or CTCs, that break away from cancers and enter the blood, often leading to the spread of cancer to other parts of the body. If more studies confirm the technology’s effectiveness, the NanoVelcro Chip device could enable doctors to access and identify cancerous cells in the bloodstream, which would provide the diagnostic information needed to create individually tailored treatments for patients with prostate cancer.
Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites in Minnesota, Florida and Arizona.
A wireless personal health monitoring system using smartphones to upload data via the Internet will revolutionize the U.S. healthcare industry, its pioneering creators say.
• Levels of 13 genes elevated in unaffected breasts of women with hormone receptor-negative breast cancer. • Eight of the genes were associated with lipid metabolism. • Ability to identify those at risk may help tailor prevention strategies.
For the first time, scientists have transplanted neural cells derived from a monkey's skin into its brain and watched the cells develop into several types of mature brain cells, according to the authors of a new study in Cell Reports. After six months, the cells looked entirely normal, and were only detectable because they initially were tagged with a fluorescent protein.
Millions of people unknowingly carry rare gene mutations that put them at high risk of developing preventable diseases such as colorectal cancer, breast cancer, and several catastrophic blood vessel disorders. University of North Carolina experts from the School of Medicine and from the Gillings School of Global Public Health propose that screening healthy adults for these and other specific, rare genetic disorders could potentially prevent these diseases.
Investigators working on the precision medicine initiative at The Cancer Institute of New Jersey are embarking on a genomic analysis study which could illuminate more options in developing personalized and precise treatments for cancer patients. It is believed that some rare and poor prognosis cancers that currently have limited treatment options may harbor genomic changes that can potentially be treated with specific targeted therapies. Through Next Generation Sequencing and data analysis of DNA in tissue samples, researchers aim to identify these changes in order to guide treatment.
Rebecca Wachs has invented a new implantable sensor with the ability to wirelessly transmit data from the site of a knee replacement, spinal fusion, or other orthopedic surgery. Simple, robust, and inexpensive to make, her sensor holds the promise of advancing personalized medicine by giving doctors an unprecedented wealth of information about how an individual patient is healing.
A healthy lung has some capacity to regenerate itself like the liver. In COPD, these reparative mechanisms fail. HDAC therapies may be useful for COPD, as well as other airway diseases. The levels of HDAC2 expression and its activity are greatly reduced in COPD patients. Decreased HDAC activity may impair the ability of the lung epithelium to regenerate.
When it comes to healing the terrible wounds of war, success may hinge on the first blood clot – the one that begins forming on the battlefield right after an injury. Researchers believe the initial response to injury may control subsequent healing.
An abdominal aortic aneurysm — a bulge in the large artery that carries blood away from the heart — can be immediately life-threatening if it grows large enough to rupture. The chance of survival when it ruptures is less than 10 percent. Many who find out they have that risk are able to have a minimally invasive repair. But up to 30 percent instead face a major open operation because of the location of the aneurysm. This new customized graft allows them, too, to have a quick recovery.
In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.
New facility at Roswell Park Cancer Institute, with support from public, private sectors, will perform whole-genome sequencing for research, clinical applications; leading bioinformatics provider CTG (NASDAQ:CTGX) to serve as technology partner
In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic “signatures” across all metastatic tumors in each patient. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity.
Using only a computer, an Internet connection, and publicly accessible online resources, a team of Whitehead Institute researchers has been able to identify nearly 50 individuals who had submitted personal genetic material as participants in genomic studies.
By analyzing tissues harvested from organ donors, Columbia University Medical Center (CUMC) researchers have created the first ever “atlas” of immune cells in the human body. Their results provide a unique view of the distribution and function of T lymphocytes in healthy individuals. In addition, the findings represent a major step toward development of new strategies for creating vaccines and immunotherapies. The study was published today in the online edition of the journal Immunity.
Researchers at the Kimmel Cancer Center at Jefferson have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers.
Johns Hopkins researchers report concrete steps in the use of human stem cells to test how diseased cells respond to drugs. Their success highlights a pathway toward faster, cheaper drug development for some genetic illnesses, as well as the ability to pre-test a therapy’s safety and effectiveness on cultured clones of a patient’s own cells.
Ge Wang, director of Virginia Tech’s Center for Biomedical Imaging, has a history of “firsts” in the imaging world, including the first paper on spiral multi-slice/cone-beam CT in 1991, on bioluminescence tomography in 2004, and on interior tomography in 2007. In a recent paper that appeared in the refereed journal PLoS One, Wang speaks about new combinations of medical imaging technologies that hold promise for improved early disease screening, cancer staging, therapeutic assessment, and other aspects of personalized medicine. The integration of multiple major tomographic scanners into a single framework is a new way of thinking in the biomedical imaging world and is evolving into a grand fusion of many imaging modalities known as omni-tomography.
An ongoing program is developing new tools for assessing health care quality from the most important viewpoint—that of the patient receiving care, according to a special supplement to Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
UC San Diego Moores Cancer Center launched a bold plan today, aimed at personalizing cancer treatment. The “My Answer to Cancer” team of oncologists, bioinformaticians, pathologists and geneticists pledges to “sequence” or analyze the DNA of large numbers of patients with cancer in order to match each patient to the best available drug for his or her particular tumor.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
People with a family history of certain diseases, including heart disease and diabetes, often underestimate their risk for developing them, even after completing a risk assessment and receiving personalized prevention messages, finds a new study in the American Journal of Preventive Medicine.
A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments. The approach, developed by investigators at Vanderbilt-Ingram Cancer Center, shows that erlotinib — a targeted therapy that acts on a growth factor receptor mutated in some lung, brain and other cancers — doesn’t simply kill tumor cells as was previously assumed. The drug also causes some tumor cells to go into a non-dividing (quiescent) state or to slow down their rate of division.
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.
Personalized medicine has promised to radically change the way we look at health and disease. Talk of tailored drug therapies and early detection of cancer has captured the attention of scientists and lay people alike. So when will patients start to reap the benefits of this medical revolution? The transition to personalized medicine won’t be seamless or swift, says Lee Gutkind, who co-authored "An Immense New Power to Heal: The Promise of Personalized Medicine" (In Fact Books, May 2012) with novelist and science writer Pagan Kennedy.
Decoding the DNA of patients with advanced breast cancer has allowed scientists at Washington University School of Medicine in St. Louis to identify distinct cancer “signatures” that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.
Technion researchers have identified a biomarker shown to predict Parkinson's disease with high accuracy. It could ID at-risk individuals before symptoms develop, when prevention treatment efforts might have the greatest impact to slow disease progression.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right